Diagnostic Capture

COVID-19

MODECULAR PCR TESTING

We’ve expanded our mission to respond to the
global Coronavirus outbreak. Learn more about
our 60 minute portable testing kit and our
Mobile Lab below.

Diagnostic Capture expanded our mission to
respond to the global Coronavirus outbreak.

We believe true safety and stability will be realized in part
through the highest quality of molecular PCR testing, and
have been working to increase these testing options on the
market. We have collaborated with various partners,
research institutions, and clinical laboratories to develop
optimized clinical protocols and fully integrated rapid
COVID-19 testing solutions to safely manage populations.
Our goal was to increase testing capacity while reducing
infection rates to help safeguard those most at risk.

We offer the below molecular PCR point of care
and high-volume mobile lab testing options today!

Point of Care Molecular PCR

Portable real-time RT-PCR
COVID-19 test kit

• 9 test results in 60 minutes!

• Field deployable with ruggedized cloud-based
smartphone reporting.

• Test anywhere, anytime, without the need to
send samples back to a laboratory

High Volume Mobile Lab

A complete turn-key solution for high-volume
COVID-19 testing

• Testing when and where you need it with same
day answers on-site!

• Test up to 10,000 people per site per day.

• Accurate and rapid results allowing you to
prioritize medical care for those in need.

Meeting Diagnosis Capture

OUR STORY

Diagnosis Capture was born out of the world-renowned Department of Radiation Oncology at
The Ohio State University. Inventor Dr. Jacob and The Ohio State University, teamed up with
Ikove Capital, to bring innovative biodosimetry solutions to the market.

OUR MISSION

Diagnosis Capture’s mission is to maximize the safety and security of global citizens in the face of viral pandemic and radiological threats. We enable first responders and government agencies to make rapid and accurate decisions necessary to save lives

TECHNOLOGY

Capture has developed technology for a minimally invasive rapid-response testing kit for emergency and first responders (both Civilian and Government) to triage radiation exposure in the event of nuclear leakage or hostile events. This groundbreaking innovation allows for the early detection of radiation toxicity via a rapid, affordable, highly-sensitive, simple blood test.

The patented technology was developed in partnership with The James Cancer Research Institute and the Wexner Medical Center, with millions in funding from the Department of Defense (DoD), the National Institutes of Health (NIH), NASA, and BARDA.

Research Funding

Our Team

A member of the OSUCCC – James Translational Therapeutic Program, Dr. Jacob is the co-inventor of two U.S. patents related to miRNA biomarkers for radiation biodosimetry and for monitoring bone-marrow reconstitution.